Pfizer Reports Lung Cancer Development In Some Exubera Users
Executive Summary
Primary lung malignancies have developed in several patients taking Pfizer's inhaled insulin Exubera, which it stopped marketing last fall, but the relationship between the adverse event and the drug remains unclear